PLx Pharma - Developing GI Safer Drugs

PL2200 Aspirin

FDA approved OTC product for treatment of pain and fever and for cardio prevention. Learn More »

Zavryl™ PL1100 Ibuprofen
PL1200 Ibuprofen

Developing GI safer Rx and OTC product for the
treatment of arthritis, pain and fever.
Learn More »

PL 4500 Indomethacin
Developing GI safer Rx products for post-operative pain and patent ductus arteriosus.
Learn More »

PLx PHARMA

Developing GI Safer Drugs

PLx is a pharmaceutical company developing GI safer formulations of proven non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin and ibuprofen for prescription and over-the-counter markets. PLx has created novel NSAID formulations, using the PLxGuard™ technology, which have the potential to reduce the serious and common gastrointestinal side- effects caused by NSAIDs.

PLx’s lead products have extensive preclinical and increasing clinical data demonstrating that the NSAID products utilizing the PLxGuard™ technology significantly reduce the risk of GI injury and are bioequivalent to their currently marketed counterpart. These products and others in development have significant market potential. See the PLx Product Pipeline.

Because PLx therapies use previously approved active ingredients, these products have an expedited regulatory path that enables faster and more cost-effective development, compared with drugs that contain novel active ingredients.

Non-Steroidal Anti-Inflammatory Drug Products:

Non-Steroidal Anti-Inflammatory Drug ProductsPLx has focused its development efforts on non-steroidal anti-inflammatory drug products that have active ingredients previously approved for marketing by the U.S. Food and Drug Administration. This strategy reduces development risks, as these active ingredients have well known safety and efficacy profiles, and speeds product development, as an expedited regulatory path called the 505(b)(2) pathway is available for new drug products containing these already approved active ingredients.

Similarly, the company has focused the development of its lead products on indications where there is a significant clinical need and large commercial opportunity, such as in osteoarthritis, pain, fever and cardioprevention, while advancing other candidates toward preclinical proof-of-concept in more niche markets, such as in ductus arteriosus. In both cases, PLx intends to enter into one or more strategic alliances with partners who can enhance the value of these products and speed their development and commercialization.

PLx Pharma
8285 El Rio, Suite 130, Houston, TX 77054 | Tel: 713-842-1249
Home | Company Profile | Products & Development | Partners | News | Contact | Sitemap

True Light Resources Site Designed by: True Light Resources
Website and Creative Design Studio
www.truelightresources.com